Aricept Complexed with Acetylcholinesterase

Revision as of 11:00, 25 November 2007 by Joel L. Sussman (talk | contribs)

THREE DIMENSIONAL STRUCTURE OF THE ANTI-ALZHEIMER DRUG, E2020 (ARICEPT), COMPLEXED WITH ITS TARGET ACETYLCHOLINESTERASE

File:1eve.gif


1eve, resolution 2.50Å

Drag the structure with the mouse to rotate

OverviewOverview

BACKGROUND: Several cholinesterase inhibitors are either being utilized, for symptomatic treatment of Alzheimer's disease or are in advanced, clinical trials. E2020, marketed as Aricept, is a member of a large family, of N-benzylpiperidine-based acetylcholinesterase (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These, inhibitors were designed on the basis of QSAR studies, prior to, elucidation of the three-dimensional structure of Torpedo californica AChE, (TcAChE). It significantly enhances performance in animal models of, cholinergic hypofunction and has a high affinity for AChE, binding to both, electric eel and mouse AChE in the nanomolar range. RESULTS: Our, experimental structure of the complex pinpoints specific, interactions responsible for the high affinity and selectivity, demonstrated previously. It shows that E2020 has a unique orientation, along the active-site gorge, extending from the anionic subsite of the, active site, at the bottom, to the peripheral anionic site, at the top, via aromatic stacking interactions with conserved aromatic acid residues., E2020 does not, however, interact directly with either the catalytic triad, or the 'oxyanion hole', but only indirectly via solvent molecules., CONCLUSIONS: Our study shows, a posteriori, that the design of E2020 took, advantage of several important features of the active-site gorge of AChE, to produce a drug with both high affinity for AChE and a high degree of, selectivity for AChE versus butyrylcholinesterase (BChE). It also, delineates voids within the gorge that are not occupied by E2020 and could, provide sites for potential modification of E2020 to produce drugs with, improved pharmacological profiles.

About this StructureAbout this Structure

1EVE is a Single protein structure of sequence from Torpedo californica with NAG and E20 as ligands. The following page contains interesting information on the relation of 1EVE with [Acetylcholinesterase]. Active as Acetylcholinesterase, with EC number 3.1.1.7 Structure known Active Sites: CAT and IHB. Full crystallographic information is available from OCA.

ReferenceReference

Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:10368299

Page seeded by OCA on Thu Nov 8 12:39:55 2007

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, Joel L. Sussman, Eran Hodis, Wayne Decatur, Jaime Prilusky, Alexander Berchansky, David Canner, Lucie Kolarova, Pham Ngoc Phuong, Angel Herraez, Michal Harel